查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1969878

全球皰疹感染疾病治療市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Herpes Infection Treatment Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計皰疹感染疾病治療市場將從 2025 年的 47.7 億美元成長到 2034 年的 86.1 億美元，2026 年至 2034 年的複合年成長率為 6.77%。

隨著單純皰疹病毒（HSV）感染在全球範圍內的增加，全球皰疹感染疾病治療市場也持續成長。人們對性行為感染感染的認知不斷提高，以及診斷技術的進步，促使更多患者尋求治療。各國政府和衛生組織也積極進行宣傳活動，以支持早期發現和醫療干預。

抗病毒藥物仍然是主要的治療選擇，隨著研究的不斷深入，其療效也不斷提高。開發中國家醫療服務的擴展正在增加患者獲得治療的機會。此外，線上藥局和遠端醫療服務的普及也使皰疹感染疾病患者更容易獲得諮詢和藥物治療。

由於疫苗研發的進步和創新抗病毒療法的開發，預計未來市場將持續成長。製藥公司不斷加大研發投入，以推出更有效、更永續的治療方法。隨著全球意識的提高和醫療基礎設施的改善，皰疹感染疾病治療市場預計將在未來幾年穩步擴張。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球皰疹感染疾病治療市場：依治療類型分類

  • 市場分析、洞察與預測
  • 抗病毒藥物
  • 局部治療
  • 疫苗
  • 支持性護理

第5章 全球皰疹感染疾病治療市場：依給藥途徑分類

  • 市場分析、洞察與預測
  • 口服
  • 局部的
  • 靜脈注射
  • 皮內給藥

第6章 全球皰疹感染疾病治療市場：依患者族群分類

  • 市場分析、洞察與預測
  • 成人
  • 青春期
  • 兒童

第7章 全球皰疹感染疾病治療市場：依感染類型分類

  • 市場分析、洞察與預測
  • 生殖器皰疹
  • 口腔皰疹

第8章 全球皰疹感染疾病治療市場：依治療環境分類

  • 市場分析、洞察與預測
  • 醫院
  • 門診部
  • 居家照護

第9章 全球皰疹感染疾病治療市場：按地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第10章 競爭格局

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第11章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • AbbVie
    • Johnson & Johnson
    • Roche
    • Mylan
    • Bristol-Myers Squibb
    • Hikma Pharmaceuticals
    • Teva Pharmaceutical Industries
    • Sanofi
    • Novartis
    • AstraZeneca
    • Pfizer
    • Merck & Co
    • Gilead Sciences
    • GlaxoSmithKline
    • Amgen
簡介目錄
Product Code: VMR112110564

The Herpes Infection Treatment Market size is expected to reach USD 8.61 Billion in 2034 from USD 4.77 Billion (2025) growing at a CAGR of 6.77% during 2026-2034.

The Global Herpes Infection Treatment Market is growing due to the increasing prevalence of herpes simplex virus (HSV) infections worldwide. Rising awareness about sexually transmitted infections and better diagnostic methods are encouraging more patients to seek treatment. Governments and health organizations are also promoting awareness programs, which support early detection and medical intervention.

Antiviral medications remain the primary treatment option, and continuous research is improving their effectiveness. The expansion of healthcare services in developing countries is increasing patient access to treatment. In addition, the availability of online pharmacies and telemedicine services is making consultation and medication access easier for patients dealing with herpes infections.

In the future, the market is expected to grow with advancements in vaccine research and innovative antiviral therapies. Pharmaceutical companies are investing in research and development to introduce more effective and long-lasting treatment options. As awareness continues to increase and healthcare infrastructure improves globally, the herpes infection treatment market is projected to expand steadily in the coming years.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Treatment Type

  • Antiviral Medications
  • Topical Treatments
  • Vaccines
  • Supportive Therapies

By Administration Route

  • Oral
  • Topical
  • Intravenous
  • Intradermal

By Patient Demographics

  • Adults
  • Adolescents
  • Pediatric

By Infection Type

  • Genital Herpes
  • Oral Herpes

By Treatment Settings

  • Hospitals
  • Outpatient Clinics
  • Home Care

COMPANIES PROFILED

  • AbbVie, Johnson Johnson, Roche, Mylan, BristolMyers Squibb, Hikma Pharmaceuticals, Teva Pharmaceutical Industries, Sanofi, Novartis, AstraZeneca, Pfizer, Merck Co, Gilead Sciences, GlaxoSmithKline, Amgen
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL HERPES INFECTION TREATMENT MARKET: BY TREATMENT TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Treatment Type
  • 4.2. Antiviral Medications Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Topical Treatments Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Supportive Therapies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL HERPES INFECTION TREATMENT MARKET: BY ADMINISTRATION ROUTE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Administration Route
  • 5.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Topical Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Intravenous Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Intradermal Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL HERPES INFECTION TREATMENT MARKET: BY PATIENT DEMOGRAPHICS 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Patient Demographics
  • 6.2. Adults Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Adolescents Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Pediatric Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL HERPES INFECTION TREATMENT MARKET: BY INFECTION TYPE 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast Infection Type
  • 7.2. Genital Herpes Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Oral Herpes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL HERPES INFECTION TREATMENT MARKET: BY TREATMENT SETTINGS 2022-2034 (USD MN)

  • 8.1. Market Analysis, Insights and Forecast Treatment Settings
  • 8.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.3. Outpatient Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.4. Home Care Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL HERPES INFECTION TREATMENT MARKET: BY REGION 2022-2034(USD MN)

  • 9.1. Regional Outlook
  • 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.2.1 By Treatment Type
    • 9.2.2 By Administration Route
    • 9.2.3 By Patient Demographics
    • 9.2.4 By Infection Type
    • 9.2.5 By Treatment Settings
    • 9.2.6 United States
    • 9.2.7 Canada
    • 9.2.8 Mexico
  • 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.3.1 By Treatment Type
    • 9.3.2 By Administration Route
    • 9.3.3 By Patient Demographics
    • 9.3.4 By Infection Type
    • 9.3.5 By Treatment Settings
    • 9.3.6 United Kingdom
    • 9.3.7 France
    • 9.3.8 Germany
    • 9.3.9 Italy
    • 9.3.10 Russia
    • 9.3.11 Rest Of Europe
  • 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.4.1 By Treatment Type
    • 9.4.2 By Administration Route
    • 9.4.3 By Patient Demographics
    • 9.4.4 By Infection Type
    • 9.4.5 By Treatment Settings
    • 9.4.6 India
    • 9.4.7 Japan
    • 9.4.8 South Korea
    • 9.4.9 Australia
    • 9.4.10 South East Asia
    • 9.4.11 Rest Of Asia Pacific
  • 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.5.1 By Treatment Type
    • 9.5.2 By Administration Route
    • 9.5.3 By Patient Demographics
    • 9.5.4 By Infection Type
    • 9.5.5 By Treatment Settings
    • 9.5.6 Brazil
    • 9.5.7 Argentina
    • 9.5.8 Peru
    • 9.5.9 Chile
    • 9.5.10 South East Asia
    • 9.5.11 Rest of Latin America
  • 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.6.1 By Treatment Type
    • 9.6.2 By Administration Route
    • 9.6.3 By Patient Demographics
    • 9.6.4 By Infection Type
    • 9.6.5 By Treatment Settings
    • 9.6.6 Saudi Arabia
    • 9.6.7 UAE
    • 9.6.8 Israel
    • 9.6.9 South Africa
    • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

  • 10.1. Recent Developments
  • 10.2. Company Categorization
  • 10.3. Supply Chain & Channel Partners (based on availability)
  • 10.4. Market Share & Positioning Analysis (based on availability)
  • 10.5. Vendor Landscape (based on availability)
  • 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL HERPES INFECTION TREATMENT INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Company Profiles
    • 11.2.1 AbbVie
    • 11.2.2 Johnson & Johnson
    • 11.2.3 Roche
    • 11.2.4 Mylan
    • 11.2.5 Bristol-Myers Squibb
    • 11.2.6 Hikma Pharmaceuticals
    • 11.2.7 Teva Pharmaceutical Industries
    • 11.2.8 Sanofi
    • 11.2.9 Novartis
    • 11.2.10 AstraZeneca
    • 11.2.11 Pfizer
    • 11.2.12 Merck & Co
    • 11.2.13 Gilead Sciences
    • 11.2.14 GlaxoSmithKline
    • 11.2.15 Amgen